Malignant pleural mesothelioma: a phase II trial with docetaxel
Authors:
- D. A. VorobiofDVD. A. Vorobiof
- B. L. RapoportBRB. L. Rapoport
- M. R. ChasenMCM. R. Chasen
- R. P. AbrattRAR. P. Abratt
- N. CronjeNCN. Cronje
- L. FourieLFL. Fourie
- G. McMichaelGMG. McMichael
- D. HackingDHD. Hacking
- 1 March 2002
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 13 (3) , 412-415
Abstract
Current cytotoxic therapy has been of limited benefit to patients with malignant pleural mesothelioma. Single agent chemotherapy has been extensively evaluated in small series of phase II clinical trials, with disappointing responses. Docetaxel, an effective taxane in the treatment of advanced breast cancer and non-small-cell lung cancer, was administered intravenously at a dose of 100 mg/m2 every 3 weeks to 30 chemotherapy naive patients with malignant pleural mesothelioma in a prospective multi-institutional phase II clinical trial. An objective response rate (partial responses) of 10% was documented. Additionally, 21% of the patients had minor responses (intention-to-treat analysis). Three patients died within 2 weeks post-first cycle of therapy, although only one patient’s death was directly attributed to the investigational drug, whilst in the majority of the patients, manageable and treatable toxicities were encountered. In this phase II clinical trial, docetaxel proved to be mildly effective in the treatment of patients with malignant pleural mesothelioma.Keywords
This publication has 11 references indexed in Scilit:
- Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group BLung Cancer, 2001
- Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma - a feasibility studyAnti-Cancer Drugs, 2000
- High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234Annals of Oncology, 1999
- Malignant pleural mesotheliomaAnnals of Oncology, 1998
- Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer.Journal of Clinical Oncology, 1998
- Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative GroupBritish Journal of Cancer, 1996
- Chemotherapy in malignant pleural mesothelioma. A review.Journal of Clinical Oncology, 1996
- Carboplatin in malignant mesothelioma: A phase II study of the cancer and leukemia Group BCancer Chemotherapy and Pharmacology, 1990
- Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape ProvinceOccupational and Environmental Medicine, 1960
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958